Compare Arqit Quantum Inc (ARQQ) vs 10X Genomics Inc (TXG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Arqit Quantum Inc vs 10X Genomics Inc — how do they compare? Arqit Quantum Inc trades at $19.11 (market cap $332.04M), while 10X Genomics Inc trades at $42.26 (market cap $5.43B). The key difference: 10X Genomics Inc is far larger — about 16.4× Arqit Quantum Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Arqit Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ARQQ | TXG | |
|---|---|---|
Market Cap | $332.04M | $5.43B |
Sector | Technology | Health |
52-Week High | $58.27 | $43.10 |
52-Week Low | $11.78 | $11.34 |
Enterprise Value | $305.35M | $4.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARQQ trades at $19.08, down 6.79% today, with a bearish technical signal from moving averages. The company reported $530K revenue for 2025 but a net loss of $35.34M, with negative profit margins and high valuation ratios. Recent news highlights contract wins and 829% YoY revenue growth in H1 FY26, though earnings misses persist.
Outlook remains speculative given deep losses and high P/S of 275.84, but growth in quantum security deals offers potential. Key risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold, indicating cautious optimism amid fundamental challenges.
TXG trades at $42.73, down 0.86% today, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue growth and beat EPS estimates, with net losses narrowing significantly from -$166M in 2022 to -$44M in 2025. Recent collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics highlight strategic expansion in diagnostics and multiomics capabilities.
Outlook remains cautiously optimistic as improving margins and cash flow support growth, but high valuation multiples and persistent net losses pose risks. Analyst consensus is mixed with a $35.14 price target below current levels, suggesting limited near-term upside despite positive operational trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
